Australian vaccine preventable disease epidemiological review series: Hepatitis B, 2000–2019
DOI:
https://doi.org/10.33321/cdi.2024.48.44Keywords:
Hepatitis B, acute Hepatitis B, chronic hepatitis B, disease surveillance, immunisation, epidemiology, vaccine preventable diseaseAbstract
Introduction
Hepatitis B vaccination was nationally funded for adolescents in 1996, with inclusion of universal infant immunisation under the National Immunisation Program (NIP) in May 2000. This study describes hepatitis B epidemiology in Australia in the two decades since 2000.
Methods
This article analyses newly-acquired (within the prior 24 months) and unspecified (all other) hepatitis B notifications (2000–2019) from the National Notifiable Diseases Surveillance System; acute hepatitis B hospitalisations (2001–2019) from the National Hospital Morbidity Database; and acute (2000–2019) and chronic (2006–2019) hepatitis B deaths from the Australian Bureau of Statistics and Australian Coordinating Registry. Rates over the reporting period were described overall, and by age group, sex, and Aboriginal and Torres Strait Islander status (Aboriginal and/or Torres Strait Islander versus other [neither Aboriginal nor Torres Strait Islander, unknown or not stated]). Trend analyses were performed using Poisson or negative binomial regression. Additional analyses were performed for the cohort born after May 2000.
Results and discussion
The annual all-age notification rate per 100,000 per year declined (p < 0.001) from 2.13 in 2000 to 0.65 in 2019 for newly-acquired hepatitis B and from 38.3 to 22.3 for unspecified hepatitis B (likely to predominantly represent chronic hepatitis B). Newly-acquired and unspecified hepatitis B notification rates were lowest among children aged < 15 years. The most substantial reductions in notification rates of newly-acquired hepatitis B were among adolescents aged 15–19 years and young adults aged 20–24 and 25–29 years (respectively 17-, 11-, and 7-fold); these age groups also recorded the most substantial reductions in unspecified hepatitis B notifications (respectively 5-, 3.5-, and 2-fold). Newly-acquired hepatitis B notification and acute hepatitis B mortality rates were two- to threefold higher in males than females. The all-age newly-acquired hepatitis B notification rate in Aboriginal and Torres Strait Islander people decreased twofold between 2000 and 2019, but remained threefold higher than in other people. Acute hepatitis B hospitalisations also declined over the study period (p < 0.001) and followed similar patterns. There were no acute or chronic hepatitis B deaths among people born after May 2000; this cohort featured 52 newly-acquired and 887 unspecified hepatitis B notifications. Due to lack of data on country of birth (and hence eligibility for infant vaccination under the NIP or overseas programs), vaccination status and likely transmission routes, we were unable to assess factors contributing to these potentially preventable infections.
Conclusion
Adolescent and infant immunisation under the NIP has led to significant reductions in notification rates of newly-acquired hepatitis B, and in acute hepatitis B hospitalisation rates, both overall and in Aboriginal and Torres Strait Islander people. Unspecified hepatitis B notification rates have also greatly decreased in children and young adults, likely largely due to the impact of overseas infant immunisation programs on prevalence in child and adolescent migrants. Work to improve completeness of variables within national datasets is crucial, along with enhanced surveillance of both newly-acquired and unspecified hepatitis B cases to investigate transmission routes, vaccination status and factors contributing to acquisition of hepatitis B, in order to optimise the impact of immunisation programs and ensure linkage with care.
Downloads
References
Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;295(7649):695–8. doi: https://doi.org/10.1016/s0140-6736(70)90926-8.
Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust. 2009;190(9):489–92. doi: https://doi.org/10.5694/j.1326-5377.2009.tb02524.x.
Struve J, Giesecke J, Lindh G, Weiland O. Heterosexual contact as a major route for transmission of acute hepatitis B among adults. J Infect. 1990;20(2):111–21. doi: https://doi.org/10.1016/0163-4453(90)93288-4.
Davis LG, Weber D, Lemon S. Horizontal transmission of hepiatitis B virus. Lancet. 1989;333(8643):889–93. doi: https://doi.org/10.1016/s0140-6736(89)92876-6.
Mahoney FJ, Stewart K, Hu H, Coleman P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med. 1997;157(22):2601–5. doi: https://doi.org/10.1001/archinte.1997.00440430083010.
Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009;7:15. doi: https://doi.org/10.1186/1741-7015-7-15.
Lettau LA, McCarthy JG, Smith MH, Hauler SC, Morse LJ, Ukena T et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med. 1987;317(20):1256–62. doi: https://doi.org/10.1056/NEJM198711123172004.
McMahon BJ, Alward WLM, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599–603. doi: https://doi.org/10.1093/infdis/151.4.599.
Van Damme P, Ward JW, Shouval D, Zanetti A. 25 – Hepatitis B vaccines. In Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Plotkin’s Vaccines (7th edition). Amsterdam: Elsevier, 2018;342–74.e17. doi: https//doi.org/10.1016/B978-0-323-35761-6.00025-0.
Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648–51. doi: https://doi.org/10.1002/hep.1840060417.
Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993;253(1337):197–201. doi: https://doi.org/10.1098/rspb.1993.0102.
McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B–related sequelae: prospective study in 1400 hepatitis B surface antigen–positive Alaska native carriers. Arch Intern Med. 1990;150(5):1051–4. doi: https://doi.org/10.1001/archinte.150.5.1051.
Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507–39. doi: https://doi.org/10.1002/hep.21513.
World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016–2021. Towards ending viral hepatitis. Geneva: WHO; June 2016. Available from: https://apps.who.int/iris/handle/10665/246177.
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081–8. doi: https://doi.org/10.1016/S0140-6736(16)30579-7.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in hepatitis B vaccination practice in Australia. Sydney: NCIRS; July 2021. [Accessed on 8 March 2022.] Available from: https://www.ncirs.org.au/sites/default/files/2021-07/Hepatitis-B-history-July%202021.pdf.
Ward K, Quinn H, Menzies R, McIntyre P. A history of adolescent school based vaccination in Australia. Commun Dis Intell Q Rep. 2013;37(2):E168–74.
Wattiaux AL, Yin JK, Beard F, Wesselingh S, Cowie B, Ward J et al. Hepatitis B immunization for indigenous adults, Australia. Bull World Health Organ. 2016;94(11):826–34A. doi: https://doi.org/10.2471/BLT.16.169524.
Ioannides S, Beard F, Larter N, Clark K, Wang H, Hendry A et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia, 2011–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.36.
Dey A, Wang H, Beard F, Macartney K, McIntyre P. Summary of national surveillance data on vaccine preventable diseases in Australia, 2012–2015. Commun Dis Intell (2018). 2019;43. doi: https://doi.org/10.33321/cdi.2019.43.58.
Kirby Institute. National update on HIV, viral hepatitis and sexually transmissible infections in Australia 2009–2018. Sydney: University of New South Wales, Kirby Institute; 4 November 2020. Available from: https://kirby.unsw.edu.au/report/national-update-hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-2009-2018.
MacLachlan JH, Stewart S, Cowie BC. Viral Hepatitis Mapping Project: geographic diversity in chronic hepatitis B and C prevalence, management and treatment. National Report 2020. Darlinghurst: Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine (ASHM); 2021. Available from: https://ashm.org.au/wp-content/uploads/2022/04/ASHM_ViralHepReport_2020_WEB_final.pdf.
MacLachlan JH, Cowie BC. Cultural and linguistic diversity of people living with chronic hepatitis B in 2011–2016: changing migration, shifting epidemiology. Aust N Z J Public Health. 2018;42(5):441–3. doi: https://doi.org/10.1111/1753-6405.12826.
New South Wales Government Department of Health (NSW Health). Additional Commonwealth and NSW-funded free vaccines. [Internet.] Sydney: NSW Health; 2020. [Accessed on 8 March 2022.] Available from: https://www.health.nsw.gov.au/immunisation/Pages/gp_catchup.aspx.
Northern Territory Government Department of Health (NT Health) Public Health Unit. NT Immunisation Schedule Adult and special risk groups. [Internet.] Darwin: NT Health; August 2021. [Accessed on 8 March 2022.] Available from: https://digitallibrary.health.nt.gov.au/prodjspui/handle/10137/775.
Queensland Government Department of Health (Queensland Health). Immunisation Schedule Queensland. [Internet.] Brisbane: Queensland Health; 22 February 2021. [Accessed on 8 March 2022.] Available from: https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule.
Government of South Australia Department of Health (SA Health). High Risk Hepatitis B Immunisation Program. [Internet.] Adelaide: SA Health; 2021. [Accessed on 8 March 2022.] Available from: https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/conditions/immunisation/immunisation+programs/high+risk+hepatitis+b+immunisation+program.
Tasmanian Government Department of Health. State-Funded Hepatitis B Vaccine for High Risk Groups in Tasmania. Hobart: Tasmanian Government Department of Health; 2020. [Accessed on 8 March 2022.] Available from: https://www.health.tas.gov.au/sites/default/files/2021-11/Hep_B_vaccine_high_risk_for_health_professionals_DoHTasmania2020.pdf.
Victoria State Government Department of Health. Immunisation schedule Victoria and vaccine eligibility criteria. [Internet.]. Melbourne: Victoria State Government Department of Health; 11 November 2021. [Accessed on 8 March 2022.] Available from: https://www.health.vic.gov.au/immunisation/immunisation-schedule-victoria-and-vaccine-eligibility-criteria.
Western Australian Government Department of Health (WA Health). Western Australian Immunisation Schedule. Perth: WA Health; 2021. [Accessed on 8 March 2022.] Available from: https://ww2.health.wa.gov.au/-/media/Files/Corporate/general-documents/Immunisation/PDF/WA-Immunisation-Schedule.pdf.
Australian Capital Territory Government Department of Health (ACT Health). Hepatitis B. [Internet.] Canberra: ACT Health; 18 March 2021. [Accessed on 8 March 2022.] Available from: https://www.health.act.gov.au/services-and-programs/immunisation/adults/hepatitis-b.
Australian Government Department of Health and Aged Care. National Immunisation Program: Free catch-up vaccines for refugees and other humanitarian entrants aged 20 years and over. Canberra: Australian Government Department of Health and Aged Care; 2017. [Accessed on 3 May 2022.] Available from: https://www.health.gov.au/sites/default/files/free-catch-up-vaccines-for-refugees-and-humanitarian-entrants-aged-20-years-and-over-fact-sheet_0.pdf.
Australian Government Department of Health and Aged Care. National Immunisation Program - Free catch-up vaccines for all individuals aged 10 to 19 years. Canberra: Australian Government Department of Health and Aged Care; 2017. [Accessed on 3 May 2022.] Available from: https://www.health.gov.au/sites/default/files/free-catch-up-vaccines-for-10-to-19-year-olds-fact-sheet-free-catch-up-vaccines-for-10-to-19-years-fact-sheet.pdf.
Australian Government Department of Health and Aged Care. Third National Hepatitis B Strategy: 2018-2022. Canberra: Australian Government Department of Health and Aged Care; 2018. Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/third-national-hepatitis-b-strategy-2018-2022.pdf.
Yohannes K, Roche PW, Roberts A, Liu C, Firestone SM, Bartlett M et al. Australia’s notifiable diseases status, 2004, annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep. 2006;30(1):1–79.
Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia. Hepatitis B (Newly acquired). Australian national notifiable diseases case definition. Canberra: Australian Government Department of Health and Aged Care; 1 July 2015. [Accessed on 8 March 2022.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/hepatitis-b-newly-acquired-surveillance-case-definition.pdf.
Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia. Hepatitis B (unspecified). Australian national notifiable diseases case definition. Canberra: Australian Government Department of Health and Aged Care; 1 July 2015. [Accessed on 8 March 2022.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/hepatitis-b-unspecified-surveillance-case-definition.pdf.
Australian Government Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS) public dataset – Influenza (laboratory confirmed). [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2022. [Accessed on 12 April 2022.] Available from: https://www.health.gov.au/resources/publications/national-notifiable-diseases-surveillance-system-nndss-public-dataset-influenza-laboratory-confirmed.
Australian Bureau of Statistics. 3101.0 – Australian Demographic Statistics, Mar 2013. Feature article: which poplulation to use for age standardisation? [Webpage.] Canberra: Australian Bureau of Statistics; 26 September 2013. [Accessed on 15 March 2023.] Available from: https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3101.0Feature+Article1Mar%202013.
Australian Institute of Health and Welfare (AIHW). Principles on the use of direct age-standardisation in administrative data collections: for measuring the gap between Indigenous and non-Indigenous Australians. Canberra: Australian Government, AIHW; 7 October 2011. Available from: https://www.aihw.gov.au/reports/indigenous-australians/principles-on-the-use-of-direct-age-standardisatio/summary.
AIHW. Indigenous identification in hospital separations data. Quality report. Canberra: Australian Government, AIHW; 2013. Available from: https://www.aihw.gov.au/getmedia/adcaf32e-d2d1-4df0-b306-c8db7c63022e/13630.pdf.
Hull BP, Dey A, Menzies RI, Brotherton JM, McIntyre PB. Immunisation coverage annual report, 2011. Commun Dis Intell Q Rep. 2013;37(4):E291–312.
Hull B, Hendry A, Dey A, Macartney K, Beard F. Immunisation coverage annual report 2019. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.18.
Hull B, Dey A, Campbell-Lloyd S, Menzies RI, McIntyre PB. NSW annual immunisation coverage report, 2011. N S W Public Health Bull. 2012;23(9–10):179–86. doi: https://doi.org/10.1071/NB12084.
Mak DB, Bulsara MK, Wrate MJ, Carcione D, Chantry M, Efller PV. Factors determining vaccine uptake in Western Australian adolescents. J Paediatr Child Health. 2013;49(11):895–900. doi: https://doi.org/10.1111/jpc.12030.
Lu X, Quinn HE, Menzies RI, Hueston L, Gilbert L, McIntyre PB. Hepatitis B seroepidemiology in Australia, one decade after universal vaccination of infants and adolescents. Infect Disord Drug Targets. 2020;20(3):341–7. doi: https://doi.org/10.2174/1871526518666181001144303.
McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology. 2020;71(4):1170–81. doi: https://doi.org/10.1002/hep.30899.
Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. Progress toward hepatitis B control – World Health Organization European Region, 2016–2019. MMWR Morb Mortal Wkly Rep. 2021;70(30):1029–35. doi: https://doi.org/10.15585/mmwr.mm7030a1.
Centers for Disease Control and Prevention (CDC). Viral Hepatitis Surveillance Report. United States, 2019. Atlanta: United States Government Department of Health and Human Services, CDC; May 2021. Available from: https://www.cdc.gov/hepatitis/statistics/2019surveillance/pdfs/2019HepSurveillanceRpt.pdf.
Sandhu HS, Roesel S, Sharifuzzaman M, Chunsuttiwat S, Tohme RA. Progress toward hepatitis B control – South-East Asia Region, 2016–2019. MMWR Morb Mortal Wkly Rep. 2020;69(30):988–92. doi: https://doi.org/10.15585/mmwr.mm6930a2.
Woodring J, Pastore R, Brink A, Ishikawa N, Takashima Y, Tohme RA. Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus – Western Pacific Region, 2005-2017. MMWR Morb Mortal Wkly Rep. 2019;68(8):195–200. doi: https://doi.org/10.15585/mmwr.mm6808a2.
Whitford K, Liu B, Micallef J, Yin JK, Macartney K, Van Damme P et al. Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis. Bull World Health Organ. 2018;96(7):484–97. doi: https://doi.org/10.2471/BLT.17.205153.
Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL et al. Universal hepatitis B vaccination in adults aged 19–59 Years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477–83. doi: https://doi.org/10.15585/mmwr.mm7113a1.
Ly KN, Xing J, Spradling PR. Trends in prevalence and characteristics of resolved and current hepatitis B among US-born persons: National Health and Nutrition Examination Survey, 2001–2018. J Infect Dis. 2021;224(5):804–12. doi: https://doi.org/10.1093/infdis/jiab224.
Iqbal K, Klevens RM, Kainer MA, Baumgartner J, Gerard K, Poissant T et al. Epidemiology of acute hepatitis B in the United States from population-based surveillance, 2006–2011. Clin Infect Dis. 2015;61(4):584–92. doi: https://doi.org/10.1093/cid/civ332.
Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, Tressler S et al. Increases in acute hepatitis B virus infections – Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR Morb Mortal Wkly Rep. 2016;65(3):47–50. doi: https://doi.org/10.15585/mmwr.mm6503a2.
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). National Hepatitis B Testing Policy 2020. Sydney: ASHM; 2020. Available from: https://testingportal.ashm.org.au/files/ASHM_TestingPolicy_2020_HepatitisB_07_2.pdf.
Australian Government Department of Health and Aged Care. Australian Immunisation Handbook. Canberra: Australian Government Department of Health and Aged Care, Australian Technical Advisory Group on Immunisation (ATAGI); 2018. Available from: https://immunisationhandbook.health.gov.au/.
Allard NL, MacLachlan JH, Tran L, Yussf N, Cowie BC. Time for universal hepatitis B screening for Australian adults. Med J Aust. 2021;215(3):103–5.e1. doi: https://doi.org/10.5694/mja2.51114.
Binka M, Butt ZA, Wong S, Chong M, Buxton JA, Chapinal N et al. Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada. World J Gastroenterol. 2018;24(11):1216–27. doi: https://doi.org/10.3748/wjg.v24.i11.1216.
Whelan J, Sonder G, Heuker J, van den Hoek A. Incidence of acute hepatitis B in different ethnic groups in a low-endemic country, 1992–2009: increased risk in second generation migrants. Vaccine. 2012;30(38):5651–5. doi: https://doi.org/10.1016/j.vaccine.2012.06.080.
Wigg AJ, Narayana SK, Hartel G, Medlin L, Pratt G, Powell EE et al. Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. J EClinicalMedicine. 2021;36:100919. doi: https://doi.org/10.1016/j.eclinm.2021.100919.
Riddell J, Hempenstall A, Nakata Y, Gregson S, Hayes R, Smith S et al. The high burden of comorbidities in Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in Far North Queensland, Australia, and the implications for patient management. PLoS One. 2023;18(4):e0284151. doi: https://doi.org/10.1371/journal.pone.0284151.
Jackson J, Sonneveld N, Rashid H, Karpish L, Wallace S, Whop L et al. Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2016–2019. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.32.
Reekie J, Kaldor JM, Mak DB, Ward J, Donovan B, Hocking JS et al. Long-term impact of childhood hepatitis B vaccination programs on prevalence among Aboriginal and non-Aboriginal women giving birth in Western Australia. Vaccine. 2018;36(23):3296–300. doi: https://doi.org/10.1016/j.vaccine.2018.04.057.
Liu B, Guthridge S, Li SQ, Markey P, Krause V, McIntyre P et al. The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. Vaccine. 2012;30(50):7309–14. doi: https://doi.org/10.1016/j.vaccine.2012.09.033.
Davies J, Li SQ, Tong SY, Baird RW, Beaman M, Higgins G et al. Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population. PLoS One. 2017;12(9):e0184082. doi: https://doi.org/10.1371/journal.pone.0184082.
Deng L, Reekie J, Ward JS, Hayen A, Kaldor JM, Kong M et al. Trends in the prevalence of hepatitis B infection among women giving birth in New South Wales. Med J Aust. 2017;206(7):301–5. doi: https://doi.org/10.5694/mja16.00823.
Graham S, MacLachlan JH, Gunaratnam P, Cowie BC. Chronic hepatitis B prevalence in Australian Aboriginal and Torres Strait Islander people before and after implementing a universal vaccination program: a systematic review and meta-analysis. Sex Health. 2019;16(3):201–11. doi: https://doi.org/10.1071/SH18150.
MacLachlan JH, Romero N, Higgins N, Coutts R, Chan R, Stephens N et al. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health. 2020;44(1):59–64. doi: https://doi.org/10.1111/1753-6405.12934.
Rowe SL, Cowie BC. Using data linkage to improve the completeness of Aboriginal and Torres Strait Islander status in communicable disease notifications in Victoria. Aust N Z J Public Health. 2016;40(2):148–53. doi: https://doi.org/10.1111/1753-6405.12434.
Australian Government Department of Health. Fifth National Aboriginal and Torres Strait Islander Blood Borne Viruses and Sexually Transmissible Infections Strategy: 2018–2022. Canberra: Australian Government Department of Health and Aged Care; 2018. Available from: https://www.health.gov.au/sites/default/files/documents/2022/06/fifth-national-aboriginal-and-torres-strait-islander-bloodborne-viruses-and-sexually-transmissible-infections-strategy-2018-2022.pdf.
Wood N, Backhouse J, Gidding HF, Gilbert GL, Lum G, McIntyre PB. Estimates of chronic hepatitis B virus infection in the Northern Territory. Commun Dis Intell Q Rep. 2005;29(3):289–90.
AIHW. Profile of Indigenous Australians. [Internet.] Canberra: Australian Government, AIHW; 2020. [Accessed on 17 March 2022.] Available from: https://www.aihw.gov.au/reports/australias-health/profile-of-indigenous-australians.
Parker C, Tong SYC, Dempsey K, Condon J, Sharma SK, Chen JWC et al. Hepatocellular carcinoma in Australia’s Northern Territory: high incidence and poor outcome. Med J Aust. 2014;201(8):470–4. doi: https://doi.org/10.5694/mja13.11117.
Condon JR, Zhang X, Dempsey K, Garling L, Guthridge S. Trends in cancer incidence and survival for Indigenous and non-Indigenous people in the Northern Territory. Med J Aust. 2016;205(10):454–8. doi: https://doi.org/10.5694/mja16.00588.
McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology. 2011;54(3):801–7. doi: https://doi.org/10.1002/hep.24442.
He WQ, Duong MC, Gidding H, MacLachlan J, Wood J, Kaldor JM et al. Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016. J Viral Hepat. 2020;27(1):74–80. doi: https://doi.org/10.1111/jvh.13202.
Reekie J, Gidding HF, Kaldor JM, Liu B. Country of birth and other factors associated with hepatitis B prevalence in a population with high levels of immigration. J Gastroenterol Hepatol. 2013;28(9):1539–44. doi: https://doi.org/10.1111/jgh.12245.
Gibson-Helm M, Teede H, Block A, Knight M, East C, Wallace EM et al. Maternal health and pregnancy outcomes among women of refugee background from African countries: a retrospective, observational study in Australia. BMC Pregnancy Childbirth. 2014;14:392. doi: https://doi.org/10.1186/s12884-014-0392-0.
Masters PJ, Lanfranco PJ, Sneath E, Wade AJ, Huffam S, Pollard J et al. Health issues of refugees attending an infectious disease refugee health clinic in a regional Australian hospital. Aust J Gen Pract. 2018;47(5):305–10. doi: https://doi.org/10.31128/AFP-10-17-4355.
Ngo CC, Maidment C, Atkins L, Eagar S, Smith MM. Blood screen findings in a 2-year cohort of newly arrived refugees to Sydney, Australia. Public Health Res Pract. 2018;28(1):2811804. doi: https://doi.org/10.17061/phrp2811804.
Heywood AE, Nothdurft H, Tessier D, Moodley M, Rombo L, Marano C et al. Pre-travel advice, attitudes and hepatitis A and B vaccination rates among travellers from seven countries. J Travel Med. 2016;24(1):taw069. doi: https://doi.org/10.1093/jtm/taw069.
Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D et al. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Supp):S1–167.
McCulloch K, Romero N, MacLachlan J, Cowie BC. National Surveillance for Hepatitis B Indicators: Measuring the progress towards the targets of the National Hepatitis B Strategy. Annual report 2020. Melbourne: WHO Collaborating Centre for Viral Hepatitis, the Doherty Institute; 2021. Available from: https://www.doherty.edu.au/uploads/content_doc/National_Surveillance_for_Hepatitis_B_Indicators_2020_final.pdf.
Australian Government Department of Health. Australian Immunisation Register link to the Multi-Agency Data Integration Project. Canberra: Australian Government Department of Health and Aged Care; 2022. [Accessed on 13 April 2022.] Available from: https://www.health.gov.au/sites/default/files/documents/2022/03/australian-immunisation-register-link-to-the-multi-agency-data-integration-project.pdf.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
